Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating

With significant hedge fund interest and a share price under $10, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

On August 8, 2025, Jefferies increased its price target on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) from $2.50 to $3.00, maintaining a ‘Hold’ rating. The price revision is driven by multiple potential catalysts through 2026, including the anticipated FDA decision on approving RP-A501, the company’s AAV9-based gene therapy for Danon heart disease. This potential breakthrough could unlock a market opportunity for RCKT that exceeds $500 million.

Furthermore, the analyst also highlighted the planned resubmission of a Biologics License Application for Kresladi, a lentiviral therapy for LAD-I, by the end of 2025. This potential opportunity is valued at over $100 million if monetized. At the same time, ongoing progress in gene therapies for inherited cardiomyopathies, including PKP2 and BAG3 programs, holds the potential to drive further growth. Despite the positives, the analyst views the company’s rapid cash burn as a concern, which drives the ‘Hold’ rating.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), based in the U.S., develops gene therapies for rare and life-threatening diseases. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of RCKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.